
GRFS vs ERAS
$GRFS vs $ERAS head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
GRFS vs ERAS: the quick read
- ·ERAS is the larger company by market cap ($5.17B vs $4.98B).
- ·ERAS has been more active on our scanner (181 vs 20 alerts in 30 days).
- ·ERAS has the smaller float (303.9M vs 680.6M), which tends to mean sharper, more volatile moves.
- ·These sit in different industries (Pharmaceutical Preparations vs PHARMACEUTICAL PREPARATIONS), so they answer to different catalysts and a move in one says little about the other.
- ·ERAS draws far more of our scanner's attention, 181 unusual-volume alerts in 30 days against 20, so it is the more actively traded of the two by some distance.
- ·They are closely matched in size, within 4% of each other on market cap, which makes the rest of this table the interesting part.
- ·ERAS is the one in play today, trading about 2.3x its normal volume, which is what puts a name on our scanner in the first place.
Objective differences only. Not investment advice.
Get the best catches in your inbox
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing GRFS and ERAS on TheDesperateTrader.
- Is GRFS or ERAS the better stock?
- "Better" depends on your goal, and these two are not alike. ERAS is the larger company by market cap ($5.17B vs $4.98B). ERAS has been more active on our scanner (181 vs 20 alerts in 30 days). ERAS has the smaller float (303.9M vs 680.6M), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between GRFS and ERAS?
- The differences that matter: they are not in the same business - GRFS is pharmaceutical preparations and ERAS is pharmaceutical preparations; they are similar in size ($4.98B vs $5.17B); they trade at very different share prices ($7.30 vs $14.77); GRFS sits at 10% of its 52-week range against 58% for ERAS; our scanner flagged GRFS 20 times in the last 30 days against 181 for ERAS. Everything above is measured from the latest completed session and SEC filings.
- Which of GRFS and ERAS is more active right now?
- Right now GRFS is at about 0.9x its normal volume and ERAS is at about 2.3x, so ERAS is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading GRFS or ERAS? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysMore GRFS and ERAS comparisons
Same sector, similar size. These are the peers each one is usually weighed against.
Explore the market
Free, live market tools. No account required to look.